| scholarly article | Q13442814 |
| P2093 | author name string | George A Omura | |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3177 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Modified Fibonacci search. | |
| P478 | volume | 21 |
| Q44390471 | An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations |
| Q58660038 | How participants in cancer trials are chosen: ethics and conflicting interests |
| Q43681160 | Incorporating adverse event relatedness into dose-finding clinical trial designs |
| Q54785499 | Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. |
| Q79463052 | Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers |
| Q92445960 | Phase I cancer clinical trials |
| Q37339628 | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer |
| Q35812808 | Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer |
| Q39348852 | Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib |
| Q40153561 | Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. |
| Q84314377 | Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies |
| Q45978270 | Some notable properties of the standard oncology Phase I design. |
| Q34348422 | What does a modified-Fibonacci dose-escalation actually correspond to? |
Search more.